文献速递慢性肾脏病肾血管病与高血压

钠摄入与肾功能关系的定量文献综述

Renal function in relation to sodium intake: a quantitative review of the literature.
PubMed 文献 · Kidney Int · 2017-04-12

该定量文献综述检索了1980年至2016年5月的PubMed文献,最终纳入36项研究(11项横断面、5项纵向观察、20项干预试验),评估钠摄入与肾功能指标的关系。横断面研究和队列研究中钠摄入与白蛋白尿、肾小球滤过率或肾脏终点无显著关联,而短期干预试验显示高钠摄入与eGFR升高及白蛋白尿增加相关。结论认为无有力证据表明长期减盐可预防或延缓慢性肾脏病,但结果不能外推至中重度CKD患者。

要点

  • 横断面研究和队列研究未发现钠摄入与肾功能指标或肾脏终点显著相关。
  • 短期干预试验中高钠摄入与eGFR升高4.6 ml/min及白蛋白尿增加53%相关。
  • 证据不支持长期减盐可预防或延缓CKD,但结果不能外推至中重度CKD。

核心结论

  • 无有力证据表明长期减少盐摄入可预防慢性肾脏病或延缓其进展。
  • 当前发现主要来自轻度肾功能损害者,不能外推至中重度慢性肾脏病患者。

研究设计与样本

  • 定量文献综述,检索PubMed 1980年1月至2016年5月同行评议文章。
  • 两名研究者筛选5072篇文献,最终提取36项研究数据。
  • 纳入研究包括11项横断面研究、5项纵向观察性研究和20项干预试验。
  • 采用逆方差加权随机效应模型合并研究内效应量,并标准化至100 mmol/d的钠梯度。

主要发现

  • 横断面研究中,白蛋白尿的合并比值比为1.23(95%CI 0.92-1.64,P=0.16)。
  • 横断面研究中,肾小球滤过率的合并均差为8.5 ml/min(95%CI -2.3至19.2 ml/min,P=0.12)。
  • 队列研究中,肾脏终点的合并相对风险为1.08(95%CI 0.92-1.29,P=0.35)。
  • 干预试验(中位持续时间14天,范围4-186天)中,高钠与低钠摄入相比,估计肾小球滤过率均差为4.6 ml/min(95%CI 3.4-5.8 ml/min,P<0.0001),白蛋白尿均差为53%(95%CI 21-84,P=0.001)。
  • Cochran Q检验显示横断面研究中eGFR和白蛋白尿均存在显著异质性(P<0.0001),干预试验中白蛋白尿存在显著异质性(P=0.04)。

临床怎么用

  • 现有证据不足以支持将限钠至2.4 g/d以下作为慢性肾脏病管理的普遍推荐。
  • 临床决策时应考虑证据主要来自轻度肾功能损害人群,中重度CKD患者需个体化评估。

局限性

  • 研究结果主要来自轻度肾功能损害者,不能外推至中重度慢性肾脏病患者。
  • 横断面研究和干预试验中存在显著异质性。
  • 干预试验持续时间较短(中位14天),长期效果不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We undertook a quantitative literature review to search for evidence underpinning current guidelines proposing a reduction of sodium intake to less than 2.4 g/d for the management of chronic kidney disease. We searched PubMed for peer-reviewed articles published from January 1980 through May 2016. Two investigators screened 5072 publications and extracted data from 36, including 11 cross-sectional and 5 longitudinal observational studies and 20 intervention trials. Within-study effect sizes were pooled and standardized to a sodium gradient of 100 mmol/d by using inverse-variance weighted random effects models. Among cross-sectional studies, the pooled odds ratio for albuminuria was 1.23 (95% confidence interval [CI], 0.92-1.64, P = 0.16), and the pooled mean difference in glomerular filtration rate amounted to 8.5 ml/min (CI, -2.3 to 19.2 ml/min; P = 0.12). In the cohort studies, the pooled relative risk of a renal endpoint was 1.08 (CI, 0.92-1.29; P = 0.35). In the intervention trials (median duration, 14 days [range, 4-186 days]), the mean differences in estimated glomerular filtration rate and albuminuria (high vs. low sodium intake) averaged 4.6 ml/min (CI, 3.4-5.8 ml/min; P < 0.0001) and 53% (CI, 21-84; P = 0.001), respectively. Cochran's Q statistic indicated significant heterogeneity among cross-sectional studies for both estimated glomerular filtration rate and albuminuria (P < 0.0001) and among intervention trials for albuminuria (P = 0.04). In conclusion, there is no robust evidence suggesting that long-term reduction of salt intake would prevent chronic kidney disease or delay its progression. However, our current findings, which were mainly obtained in people with slight renal impairment, cannot be extrapolated to patients with moderate or severe chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Nomura K, Asayama K, Jacobs L, et al. Renal function in relation to sodium intake: a quantitative review of the literature. Kidney Int. 2017. PMID: 28412019. doi:10.1016/j.kint.2016.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。